DNA vs. MRNA
Compare and contrast key facts about Ginkgo Bioworks Holdings, Inc. (DNA) and Moderna, Inc. (MRNA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: DNA or MRNA.
Performance
DNA vs. MRNA - Performance Comparison
Returns By Period
In the year-to-date period, DNA achieves a -90.46% return, which is significantly lower than MRNA's -62.50% return.
DNA
-90.46%
-27.36%
-77.95%
-89.46%
N/A
N/A
MRNA
-62.50%
-31.07%
-74.05%
-52.77%
13.09%
N/A
Fundamentals
| DNA | MRNA | |
|---|---|---|
| Market Cap | $366.14M | $16.73B |
| EPS | -$12.89 | -$5.81 |
| Total Revenue (TTM) | $217.95M | $5.08B |
| Gross Profit (TTM) | $138.89M | $3.35B |
| EBITDA (TTM) | -$626.41M | -$2.41B |
Key characteristics
| DNA | MRNA | |
|---|---|---|
| Sharpe Ratio | -0.90 | -0.86 |
| Sortino Ratio | -2.31 | -1.24 |
| Omega Ratio | 0.75 | 0.85 |
| Calmar Ratio | -0.90 | -0.55 |
| Martin Ratio | -1.39 | -1.42 |
| Ulcer Index | 64.17% | 36.11% |
| Daily Std Dev | 99.18% | 59.59% |
| Max Drawdown | -99.10% | -92.39% |
| Current Drawdown | -98.92% | -92.30% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between DNA and MRNA is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
DNA vs. MRNA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
DNA vs. MRNA - Dividend Comparison
Neither DNA nor MRNA has paid dividends to shareholders.
Drawdowns
DNA vs. MRNA - Drawdown Comparison
The maximum DNA drawdown since its inception was -99.10%, which is greater than MRNA's maximum drawdown of -92.39%. Use the drawdown chart below to compare losses from any high point for DNA and MRNA. For additional features, visit the drawdowns tool.
Volatility
DNA vs. MRNA - Volatility Comparison
Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 27.65% compared to Moderna, Inc. (MRNA) at 17.49%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
DNA vs. MRNA - Financials Comparison
This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities